Squamous Cell Carcinoma of Skin: Risk Stratification, Mohs Surgery, and Adjuvant Therapy

Clinical Overview

Squamous cell carcinoma (SCC) of the skin is the second most common cutaneous malignancy after basal cell carcinoma, with more than 700,000 cases diagnosed annually in the United States. SCC arises from malignant transformation of keratinocytes in the epidermis. Unlike basal cell carcinoma, SCC has significant metastatic potential (approximately 2-5% of cutaneous SCCs develop regional or distant metastases), making accurate risk stratification and appropriate treatment critical. Early detection and treatment of low-risk SCC results in excellent prognosis, while high-risk tumors (large size, poor differentiation, deep invasion, immunocompromised host) carry substantially worse outcomes necessitating aggressive treatment and surveillance.

Epidemiology & Risk Factors

SCC predominantly affects older individuals with cumulative lifetime sun exposure. Fair skin phototypes (Fitzpatrick I-III) are at markedly increased risk. Incidence increases exponentially with age, with peak incidence in the 7th-8th decade. Geographic location influences incidence: areas with high UV index (southwestern United States, Australia) have 5-10 times higher incidence. Cumulative UV exposure is the primary risk factor. Additional risk factors include: immunosuppression (particularly solid organ transplant recipients who have 40-250 times higher incidence), chronic scarring from burns or chronic wounds (Marjolin ulcer), arsenic exposure, ionizing radiation (especially to areas of prior radiotherapy), and chronic inflammatory dermatoses (lichen sclerosus, discoid lupus erythematosus). Transplant recipients develop aggressive, frequently recurrent SCCs at young ages requiring intensive surveillance and prophylactic treatment with topical retinoids or photodynamic therapy.

Pathophysiology

SCC arises through malignant transformation of keratinocytes in the basal and suprabasal layers of the epidermis. Ultraviolet radiation causes thymine dimers in DNA with characteristic C-to-T transitions at dipyrimidine sites. Mutation of TP53 tumor suppressor gene is present in >90% of cutaneous SCCs, representing the initiating event in most cases. Loss of p53 function removes cell cycle checkpoint control and apoptosis mechanisms, allowing accumulation of additional mutations. Additional driver mutations include: CDKN2A (cyclin-dependent kinase inhibitor), HRAS (Harvey rat sarcoma oncogene), and PIK3CA (phosphatidylinositol 3-kinase catalytic subunit alpha). Infiltrative growth pattern (as opposed to well-circumscribed nodular growth) is associated with increased expression of matrix metalloproteinases and enhanced invasion capabilities. Poor differentiation (defined as <75% keratinization) indicates more aggressive biology with higher metastatic potential.

Clinical Presentation & Classification

SCC typically presents as a firm, erythematous, often scaly papule, nodule, or ulcerated lesion on sun-exposed skin (face, ears, dorsal hands, lower lip). The lesion may have a pearly appearance with telangiectasia or appear hyperkeratotic with a horn-like projection (cutaneous horn). Early lesions may be subtle; later-stage lesions frequently show ulceration and bleeding. Well-differentiated SCC grows slowly (months to years) and may appear clinically benign. Poorly differentiated or high-grade SCC may grow more rapidly and appear more aggressive clinically. Spindle cell variant presents as firm nodule and carries higher metastatic risk. Adenosquamous SCC (containing mucin-producing glandular differentiation) carries particularly high metastatic risk. In situ SCC (Bowen disease) is confined to the epidermis with virtually zero metastatic risk if adequately treated.

Diagnosis & Staging

Clinical diagnosis is based on characteristic appearance; however, biopsy confirmation is essential because clinical appearance does not reliably correlate with risk. Punch or shave biopsy is appropriate for diagnosis. Histopathology determines: grade of differentiation (well, moderately, poorly differentiated), depth of invasion (Clark level and invasion depth in millimeters), presence of perineural invasion (indicates aggressive behavior and higher metastatic risk), pattern of invasion (pushing borders vs. infiltrative), and subtype (spindle cell, adenosquamous, etc.). TNM staging for cutaneous SCC incorporates: tumor size (<20mm vs. ≥20mm), invasion depth (Clark level, invasion depth), grade of differentiation (well vs. poorly), and location on face vs. non-face. High-risk features include: diameter ≥20mm, Clark level IV-V invasion, poor differentiation, perineural invasion, location on central face/ears/pre-auricular/post-auricular area, immunocompromised host, or recurrent tumor. Tumor Stage T1 is <20mm, T2 is ≥20mm. N0 indicates no nodal metastases; N1-3 indicates regional nodal involvement. M0 indicates no distant metastases. Patients with regional or distant metastases (Stage III-IV) have substantially worse prognosis requiring systemic therapy consideration.

Treatment Algorithm

Treatment depends on risk stratification. Low-risk SCC (<20mm, well-differentiated, Clark level I-II, non-facial location, immunocompetent host) can be treated with standard surgical excision with 4-6mm margins, achieving 5-year recurrence rates of 2-5%. High-risk SCC (≥20mm, poorly differentiated, Clark level ≥IV, perineural invasion, facial/ear location, immunocompromised host) should be treated with Mohs micrographic surgery when feasible, achieving 5-year recurrence rates of 1-5% even for high-risk lesions. Mohs surgery allows real-time microscopic margin assessment and removal of additional tissue only where tumor persists, maximizing margin clearance while minimizing normal tissue removal. For SCCs with perineural invasion or Clark level IV-V, consideration of adjuvant radiotherapy is appropriate. Adjuvant radiotherapy (typically 5000-6000 cGy in standard fractionation, 200 cGy per fraction, 5 days per week for 5-6 weeks) improves local control and reduces recurrence rates, particularly for high-risk features. Systemic therapy is indicated for metastatic SCC: platinum-based chemotherapy (cisplatin 75mg/m² IV day 1, with 5-fluorouracil 750mg/m² IV continuous infusion days 1-5, repeated every 21 days) achieves response rates of 40-60% but is associated with significant toxicity. Cetuximab (a monoclonal antibody against EGFR) 400mg/m² loading dose IV weekly followed by 250mg/m² weekly shows activity in metastatic SCC, particularly in combination with radiotherapy or chemotherapy. For advanced SCC unfit for chemotherapy, immunotherapy with pembrolizumab or nivolumab may be considered, with emerging evidence for benefit in SCC.

Prognosis & Survival

Low-risk SCC has excellent prognosis: 5-year recurrence rates of 2-5% with standard excision, improving to 1-3% with Mohs surgery. Five-year overall survival exceeds 95% for Stage I disease. High-risk features substantially worsen prognosis: poorly differentiated grade, Clark level IV-V, perineural invasion, and large size (≥20mm) each independently increase recurrence risk to 10-40%. Immunocompromised patients, particularly transplant recipients, have 3-5 times higher recurrence rates and more aggressive disease behavior. Regional metastatic disease (Stage III) has 5-year overall survival of 40-60% with multimodal therapy (surgery and adjuvant radiotherapy). Distant metastatic SCC (Stage IV) has median survival of 6-12 months with palliative care, though chemotherapy or immunotherapy may extend survival modestly in selected patients with good performance status.

When to See a Dermatologist

Any new or changing lesion on sun-exposed skin warrants evaluation. Particularly concerning features include: rapidly enlarging lesion, non-healing ulcer, lesion with bleeding or drainage, or firm erythematous papule/nodule that persists. Individuals with fair skin and significant cumulative sun exposure should have annual skin examinations. Immunocompromised patients (transplant recipients, HIV-positive individuals, patients on chronic immunosuppressive therapy) should have surveillance every 3-6 months. Patients with prior SCC have 40-50% risk of developing additional SCCs and require surveillance every 6-12 months.

Frequently Asked Questions

Will my squamous cell carcinoma spread to my lymph nodes or lungs?

Approximately 2-5% of cutaneous SCCs develop regional or distant metastases. Risk depends on tumor characteristics: low-risk tumors (<20mm, well-differentiated, no perineural invasion) have <2% metastatic risk, while high-risk tumors (>20mm, poorly differentiated, perineural invasion, Clark level IV-V) have 10-30% metastatic risk. If your tumor has high-risk features, your doctor may recommend sentinel lymph node biopsy or imaging (ultrasound of regional nodes, chest imaging) to screen for early metastatic disease.

What does Clark level mean in my pathology report?

Clark level describes how deeply the cancer invades the skin: Level I indicates in situ (confined to epidermis), Level II indicates invasion into papillary dermis, Level III indicates invasion filling papillary dermis, Level IV indicates invasion into reticular dermis, and Level V indicates invasion into subcutaneous fat. Deeper invasion (higher Clark level) indicates more aggressive tumor biology with increased metastatic risk, influencing treatment recommendations (e.g., Mohs surgery, adjuvant radiotherapy for Clark IV-V).

I have immunosuppression from a transplant. How frequently should I be monitored for skin cancer?

Transplant recipients have 40-250 times higher incidence of cutaneous SCC compared to immunocompetent individuals. Recommended surveillance is every 3-6 months with total-body skin examination. Additionally, prophylactic systemic retinoid therapy (acitretin 0.5-1.0mg/kg daily) or topical retinoids and photodynamic therapy may reduce SCC development. Counseling on sun protection, including sunscreen (SPF 30+), protective clothing, and avoidance of intense sun exposure, is essential.

My SCC was treated but recurred 2 years later. What's my risk of future recurrences?

Recurrent SCC indicates more aggressive tumor biology and substantially increases risk of additional recurrences. Patients with prior recurrent SCC have 50-60% risk of developing another SCC within 5 years. Management includes retreatment with Mohs surgery (preferred) with close surveillance every 3-6 months. Adjuvant radiotherapy may be considered if not previously used. Prophylactic topical treatments (retinoids, 5-fluorouracil cream, or photodynamic therapy) are often recommended to reduce risk of additional SCC development.

References

Last updated: March 2026. This article reflects current evidence-based clinical practice and is intended for healthcare professionals and informed patients. Always consult with a board-certified dermatologist for personalized medical advice.